| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Institute of Immunology, University Hospital, Hamburg, Germany;
The Jackson Laboratory, Bar Harbor, ME 04609;
Université Denis Diderot, Paris, France;
The Trudeau Institute, Saranac Lake, NY 12983; and
¶ University of California, San Francisco, CA 94143
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionDisclosuresReferences |
|---|
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionDisclosuresReferences |
|---|
Treatment of T cells with the ART substrate, NAD+, affects cell proliferation, cytotoxicity, homing, TCR clustering, and survival (6, 7, 8, 9, 10). We have recently discovered that ADP-ribosylation activates the P2X7 purinoceptor (7). P2X7 is a member of the P2X family of ATP-gated ion channels and is widely expressed on blood cells (11, 12). P2X7 has sparked interest because of its peculiar ability to induce the formation of a large nonselective membrane pore (13). Activation of P2X7 with millimolar concentrations of ATP triggers calcium flux, phosphatidylserine (PS) exposure, shedding of CD62L, and apoptosis (14, 15). The same effects are triggered by NAD at micromolar concentrations via ADP-ribosylation of P2X7 (7). The effects are not observed in ART2-deficient T cells, demonstrating that activation of P2X7 by NAD is ART2 dependent (7, 16). Two commonly used strains of laboratory mice (BALB/c and C57BL/6) carry allelic variants of the P2x7 gene locus, which dramatically affects the susceptibility of T cells from these mice to ecto-NAD and ecto-ATP (8, 17). BALB/c T cells that express wild-type P2X7 are sensitive to NAD and ATP, whereas C57BL/6 T cells that express the P451L allelic variant of P2X7 are resistant (7).
The type II transmembrane protein CD38 is a potent ecto-NAD-glycohydrolase (ecto-NADase) (18, 19). CD38 is expressed by lymphocytes, macrophages, endothelial cells, dendritic cells, pancreatic islet cells, and several other cell types. A soluble form of CD38, presumably generated by proteolytic cleavage of its juxtamembrane stalk, has been found in human serum and other extracellular fluids (18). CD38-deficient mice show normal development of the major lymphocyte subsets, but show impaired humoral immune responses, neutrophil chemotaxis, and dendritic cell trafficking (20, 21, 22). The dramatic reduction in NADase activity in tissues of CD38–/– vs wild-type mice indicates that CD38 is the predominant NADase in most murine tissues, including lymph node, spleen, and bone marrow (21).
It has been proposed that the classic intracellular metabolites of energy metabolism, NAD and ATP, also play roles as signaling molecules in the extracellular environment (23, 24, 25). The plasma membrane of living cells is impermeable to these nucleotides, but they can be released from cells by lytic and nonlytic mechanisms (26, 27). The fate of extracellular signaling molecules (ligands, transmitters) is determined by the rate of their release, metabolism, reuptake by cells, and/or renal excretion. For example, the concentration of ATP and the duration of signaling via ATP in the extracellular compartment are controlled by CD39 and related ectonucleotidases, which hydrolyze ATP to ADP and/or AMP (28, 29). The purpose of this study was to determine whether the ecto-NADase CD38 similarly controls the signaling function of NAD by limiting the availability of NAD as a substrate for ART-catalyzed ADP-ribosylation of cell surface proteins. A recently described immunoassay for monitoring ADP-ribosylation of cell surface proteins on living cells by flow cytometry (30), CD38–/– and ART2–/– mice (16, 20), and the CD38 inhibitor nicotinamide 2'-deoxy-2'-fluoroarabinoside adenine dinucleotide (araF-NAD) (31) provided useful tools to address this question. Our results show that CD38, indeed, controls the level of ART2-catalyzed ADP-ribosylation of cell surface proteins.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionDisclosuresReferences |
|---|
ADP-ribose, ATP, NAD, and 1,N6-ethenonicotinamide adenine dinucleotide (etheno-NAD) were obtained from Sigma-Aldrich (Fig. 1). PE- and FITC-conjugated mAbs and Annexin V were purchased from BD Pharmingen/BD Biosciences, including anti-CD3
(145-2C11), anti-CD4 (RM4-5), anti-CD8 (53-5.8), anti-CD38 (90), and anti-CD45R/B220 (RA3-6B2). The anti-ART2 Ab (Ali) was raised in our lab by genetic immunization (32) and recognizes a common epitope on ART2.1 and ART2.2. For the sake of brevity, "ART2" is used instead of "ART2.1 and ART2.2" throughout this paper. Fluorochrome conjugation of Ali and the anti-ethenoadenosine Ab 1G4 (30) was performed using the Alexa Fluor 488 labeling kit from Molecular Probes. [32P]NAD was obtained from Amersham Biosciences.
|
BALB/c and C57BL/6 mice were obtained from The Jackson Laboratory or Charles River. Cd38–/– mice (20) and Art2–/– mice (16) were backcrossed onto the BALB/c and C57BL/6 backgrounds for 8–12 generations. The ART2–/– lines are deficient in both, ART2.1 and ART2.2 (16). Single-cell suspensions were prepared from lymph nodes and spleen of sacrificed animals in RPMI 1640 medium by passage through Nitex membrane (110-µm mesh; Tetko). CD38+ cells were depleted using anti-CD38PE and anti-PE MicroBeads with VarioMACS and AS columns according to the manufacturer’s instructions (Miltenyi Biotec).
Incubation of cells with etheno-NAD and staining with 1G4
For monitoring etheno-ADP-ribosylation of cell surface proteins on living cells (30), cells (106/100 µl of RPMI 1640 medium) were incubated with or without the indicated concentrations of etheno-NAD at 37°C, washed, and stained with 1G4Alexa488 (1 µg) for 30 min at 4°C. Cells were costained with saturating amounts of fluorochrome-conjugated Abs against other cell surface proteins as indicated in the figures. Where indicated, cells were preincubated with araF-NAD (Fig. 1) (31) before etheno-NAD treatment for 10 min at room temperature. Ab-stained cells were washed and resuspended in 250 µl of RPMI 1640 and 10 µl of propidium iodide (PI; 10 µg/ml; Molecular Probes) and analyzed by flow cytometry on a FACSCalibur (BD Biosciences) as described previously (32). Mean fluorescence intensity (MFI) of gated cells was calculated with CellQuest (BD Biosciences), and diagrams were produced with Excel (Microsoft).
Enzyme assays
A total of 2 x 106 cells was preincubated with araF-NAD (0–10 µM) in 10 µl of RPMI 1640 medium for 15 min at room temperature. An equal volume (10 µl) of RPMI 1640 medium containing 4 µM NAD, 2 µCi of [32P]NAD, and 8 mM agmatine was added to the reaction. Cells were incubated for 30 min at 37°C. Cells were pelleted by centrifugations, and cell supernatants were analyzed by TLC on polyethyleneimine cellulose (Merck) as described previously (33).
Assay for PS exposure and PI staining
Single-cell suspensions from lymph nodes were prepared, and B cells were depleted using magnetic cell separation with Dynabead-immobilized goat anti-mouse IgG (Dynal) as described (7). Purity of T cells was always >95% as verified by FACS analyses using PE-conjugated anti-B220 and FITC-conjugated anti-CD3. Following treatment with NAD or ATP for 45 min at 37°C, cells were washed in RPMI 1640 medium adjusted to 2 mM CaCl2, and were stained for 20 min on ice with FITC-conjugated Annexin V (1 µg/ml) (BD Biosciences) and PI (10 µg/ml) before flow cytometry.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionDisclosuresReferences |
|---|
Murine lymphocytes have been shown to express at least two distinct NAD-metabolizing ectoenzymes, the GPI-anchored ecto-ADP-ribosyltransferase ART2 and the type II transmembrane bifunctional NADase/ADP-ribosylcylase CD38. Whereas ART2 reportedly is expressed by peripheral T cells and is shed upon T cell activation (33), CD38 is expressed by B cells and by activated T cells (20, 34). Fig. 2 shows FACS profiles of splenocytes and purified lymph node T cells from C57BL/6, BALB/c, and respective CD38–/– and ART2–/– mice after staining for ART2, CD38, CD3, and B220. As reported previously, CD38–/– and ART2–/– mice do not show any marked deviations from wild-type proportions of the major splenic lymphocyte subpopulations (16, 20). Also, in accord with previous reports, CD38 is expressed at high levels on B220+ cells (namely B cells), whereas most T cells are CD38low or CD38– (Fig. 2, A and C). Expression of ART2 is restricted to B220– cells (T cells), and only a small population of ART2+ cells coexpresses CD38. Note that ART2 is expressed at higher levels on C57BL/6 than BALB/c T cells, as observed previously (32).
|
Many extracellular ligands such as ATP or acetylcholine are degraded hydrolytically by specific enzymes, which thereby limit the availability of the ligand for its receptor. Because CD38 is known to possess potent NADase activity, we reasoned that CD38 might influence the substrate availability for NAD-dependent ADP-ribosyltransferase ART2. To address this question, we compared cell surface protein ADP-ribosylation of lymphocytes from wild-type, CD38–/–, and ART2–/– mice. To this end, we treated splenocytes (Fig. 2B) and purified lymph node T cells (Fig. 2D) with etheno-NAD, which is an efficient substrate for CD38 and ARTs (30, 35), and then detected etheno-ADP-ribosylated proteins with etheno-adenosine-specific mAb 1G4. In accord with the expression pattern of ART2, cell surface etheno-ADP-ribosylation is restricted to B220– cells (Fig. 2B). Interestingly, cells from CD38-deficient mice show enhanced cell surface etheno-ADP-ribosylation in comparison with their wild-type counterparts (Fig. 2, B and D). Cells from ART2-deficient mice do not show any etheno-ADP-ribosylation, indicating that ART2 is the only ART activity on splenic and lymph node T cells. Dose-response analyses further demonstrate the striking differences in apparent cell surface ART activity between CD38–/– and wild-type cells (Fig. 3). Following incubation of cells with etheno-NAD, both CD4+ and CD8+ T cell subsets show dose-dependent staining with 1G4 (Fig. 3B). In contrast, CD4– and CD8– cells show little if any staining with 1G4. CD8+ cells exhibit brighter 1G4 staining than CD4+ cells, in accord with the higher level of ART2 expression by CD8+ vs CD4+ cells (Fig. 3A) (32). Strikingly, at low concentrations of exogenous NAD (<50 µM), cells from wild-type mice show much lower apparent ART activity than cells from CD38-deficient mice. At high levels of exogenous NAD (>50 µM), wild-type cells show similar if not slightly stronger levels of cells surface etheno-ADP-ribosylation.
|
Because T cells express only low levels of CD38, but B cells express very high levels of CD38 (Fig. 2), the differences in cell surface ADP-ribosylation of CD38–/– vs wild-type cells (Fig. 3) could, in principle, be explained by low levels of CD38 acting in cis on the T cell surface and/or by high levels of CD38 acting in trans on the B cell surface. To investigate whether ADP-ribosylation of cell surface proteins can be influenced in trans by the presence of cells expressing CD38, we removed CD38+ cells by magnetic cell separation. CD38-depleted and total splenocytes were then incubated with or without etheno-NAD and stained with fluorochrome-conjugated 1G4 and anti-CD38 Abs (Fig. 4A). Double staining of total splenocytes revealed prominent 1G4 staining of CD38low and CD38– cells, but little if any 1G4 staining of CD38high cells (the latter correspond to ART2– B cells; see Fig. 2). Moreover, depletion of CD38high cells, indeed, resulted in strongly enhanced 1G4 staining of CD38– and CD38low cells. Similar results were obtained with splenocytes prepared from C57BL/6 and BALB/c mice (Fig. 4, B and C). Note, however, that BALB/c cells exhibit lower levels of etheno-ADP-ribosylation than C57BL/6 cells (Fig. 4, C vs B), in accord with the lower level of ART2 expression by BALB/c cells (Fig. 2A).
|
The results obtained so far show that the presence of CD38 can influence cell surface protein ADP-ribosylation on a distinct cell population. To determine whether CD38+ cells inhibit ADP-ribosylation in trans by limiting substrate availability, we adapted our 1G4-based FACS assay as a bioassay for assessing ecto-etheno-NAD concentrations available for ADP-ribosylation. To this end, supernatants were harvested from wild-type or CD38–/– splenocytes that had been incubated with etheno-NAD for 20 min, and these supernatants were used as a source of etheno-NAD for cells that had not been exposed to etheno-NAD (Fig. 5). By comparing 1G4 staining of these cells in FACS analyses, it was possible to estimate the reduction in etheno-NAD levels following a 20-min incubation of cells with etheno-NAD. Fig. 5A shows comparative FACS analyses of splenocytes following a 20-min incubation either with 12.5 µM etheno-NAD or with the supernatant harvested from cells after a 20-min incubation with 12.5 µM etheno-NAD. The results show that incubation of wild-type cells with etheno-NAD for 20 min dramatically reduces the level of substrate available for subsequent etheno-ADP-ribosylation, as reflected by the much lower level of 1G4 staining of cells incubated with supernatant of etheno-NAD-treated cells than of cells incubated with fresh etheno-NAD (Fig. 5A, panel 3 vs panel 2). In striking contrast, incubation of CD38–/– cells with etheno-NAD for 20 min had little if any effect on substrate available for subsequent etheno-ADP-ribosylation as reflected in similar 1G4-staining levels of cells incubated with supernatant and with fresh etheno-NAD (Fig. 5A, panel 6 vs panel 5). Dose-response analyses confirm that wild-type splenocytes catabolize etheno-NAD in a dose-dependent manner (Fig. 5B, left panel). Low levels of ecto-etheno-NAD (<5 µM) are completely catabolized by wild-type splenocytes within 20 min. Wild-type cells quite efficiently catabolize even much higher concentrations of etheno-NAD (50% hydrolysis of 50 µM etheno-NAD within 20 min). In contrast, CD38–/– splenocytes show little if any capacity to metabolize even low levels of etheno-NAD (Fig. 5B, right panel).
|
The results shown so far indicate that CD38 influences ART2-mediated ADP-ribosylation of cell surface proteins by catabolizing the substrate NAD. If so, specifically inhibiting the NAD-metabolizing activity of CD38 should increase the substrate availability and thereby indirectly enhance ART2-catalyzed cell surface ADP-ribosylation. araF-NAD, in which the ribose group adjacent to the nicotinamide moiety of NAD is replaced by fluoroarabinoside (see Fig. 1), has been described as a very potent, nonhydrolyzable inhibitor of splenocyte ecto-NADases (31). However, it was not known whether araF-NAD affects ARTs. To assess the effects of araF-NAD on CD38 and ART2, we preincubated wild-type or CD38–/– splenocytes with araF-NAD for 20 min before exposure to etheno-NAD and then measured cell surface etheno-ADP-ribosylation using the 1G4-based FACS assay. In these experiments, we used mAb B220 to stain B cells and then analyzed ADP-ribosylation on T cells by gating on cells lacking B220. The results shown in Fig. 6A reveal a dose-dependent enhancement of cell surface protein etheno-ADP-ribosylation by araF-NAD in case of wild-type B220– splenocytes, whereas araF-NAD had little if any influence on cell surface etheno-ADP-ribosylation by B220– splenocytes from CD38–/– mice. Kinetic analyses confirmed the potent dose-dependent stimulation of cell surface etheno-ADP-ribosylation following preincubation with araF-NAD for 20 min in the case of wild-type but not CD38–/– splenocytes (Fig. 6B). These results indicate that the apparent stimulatory effect of araF-NAD on cell surface ADP-ribosylation is mediated indirectly by its inhibition of CD38 rather than by a direct action on ART2.
|
|
ADP-ribosylation of T cell surface proteins upon incubation of cells with ecto-NAD activates the P2X7 purinoceptor (7). As in the case of P2X7 activation by high doses of ATP, this induces shedding of CD62L, exposure of PS, and staining with PI. Cells lacking ART2 are resistant to NAD-induced apoptosis but still undergo apoptosis in response to ATP provided that the P2X7 receptor is functional. Cells expressing the P451L variant of the P2X7 receptor are resistant to both NAD- and ATP-mediated activation of P2X7. Remarkably, even in the absence of exogenously added NAD or ATP, a small but distinct subpopulation of lymph node T cells from wild-type mice but not from ART2–/– mice exposed PS and lacked CD62L. We hypothesized that this spontaneous exposure of PS and loss of CD62L might reflect ADP-ribosylation consequential to the release of endogenous NAD from cells in situ and/or during the preparation of lymph node cells (7, 16). If so, we reasoned that lymph node cells from CD38–/– mice, which lack the major NAD-hydrolyzing activity, should encounter higher levels of endogenous ecto-NAD under these conditions, and therefore, should show higher levels of PS and lower levels of CD62L on the cell surface. To test this hypothesis, we analyzed Annexin V/PI and CD62L staining of lymph node T cells from BALB/c wild-type and CD38–/– mice in the absence of exogenously NAD or ATP (Fig. 8A). Indeed, a much larger subpopulation of cells from CD38–/– mice than from wild-type or ART2–/– mice showed spontaneous staining by Annexin V (39%) and PI (28%). Moreover, a large fraction (38 of 67 = 58%) of CD3+ cells from these mice did not stain for CD62L (vs 43% of wild-type T cells; Fig. 8B). The fact that cells from ART2-deficient mice contain little if any cells exposing PS (8%) (Fig. 8A) and only a small fraction of cells lacking CD62L (15%) (B) argues that these effects are mediated by ART2-catalyzed endogenous ADP-ribosylation.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionDisclosuresReferences |
|---|
Our results show that CD38, indeed, controls the level of ART2-catalyzed cell surface protein ADP-ribosylation and indicate that CD38 exerts this control not only in cis on the same cell surface as ART2, but also in trans on the surface of other cells. Thus, transfection of ART2 into lymphoma cells lacking CD38 results in much higher levels of cell surface ADP-ribosylation than transfection into cells expressing CD38 (results not shown). Moreover, purified T cells from CD38–/– mice show stronger ADP-ribosylation of cell surface proteins than cells from wild-type mice, especially at lower and more physiological concentrations of ecto-NAD (Fig. 2D). The effect of CD38 on ADP-ribosylation in cis is moderate, reflecting the low level of CD38 on T cells. A stronger effect of CD38 in trans becomes apparent when comparing levels of cell surface ADP-ribosylation by wild-type vs CD38–/– T cells in total splenocyte populations (Figs. 2B and 3). In this situation, wild-type T cells are in the company of cells expressing high levels of CD38 (wild-type B cells), whereas CD38–/– T cells are in the company of cells lacking CD38. Consistently, removal of CD38+ cells from suspensions of wild-type splenocytes markedly enhances the degree of cell surface ADP-ribosylation by the remaining cells (Fig. 4).
The finding that araF-NAD, a specific inhibitor of CD38-mediated NAD-hydrolysis, enhances ADP-ribosylation by wild-type but not by CD38–/– T cells (Figs. 6 and 7) further supports the conclusion that CD38 controls ART2-catalyzed protein ADP-ribosylation. This finding is of import also to studies aimed at developing inhibitors of CD38 for experimental and therapeutic modulation of immune functions (39). Our results demonstrate that such inhibitors can indirectly effect ADP-ribosylation reactions catalyzed by ecto-ARTs by increasing the levels of ecto-NAD. Our results may also be relevant to other studies using CD38–/– mice as some of the immune phenotypes reported for these mice may be due to enhanced ADP-ribosylation of target proteins by ARTs consequential to the inefficient removal of ecto-NAD in these mice (20, 22, 40, 41, 42). Note that all of the studies published to date have been conducted using CD38-deficient mice on the C57BL/6 background expressing the functionally impaired P451L variant of P2X7. Thus, if ARTs affected the immune phenotypes in these mice, it is more likely that this is mediated by ADP-ribosylation of LFA-1 and other targets rather than by ART-mediated activation of P2X7.
The rapid consumption of exogenously added etheno-NAD and [32P]NAD by CD38-expressing splenocytes but not by CD38–/– cells (Figs. 4 and 6) implies that local concentrations of NAD may vary dramatically in vivo, depending on the presence of CD38-expressing cells and/or soluble CD38. Considering that cells in the experimental setting are suspended in a much larger volume of extracellular medium (107 cells/ml) than in vivo (2 x 108 splenocytes in a total volume of 250 µl) suggests that ecto-NAD is metabolized even faster in the surroundings of CD38-expressing cells in vivo than in the experimental situation illustrated in Fig. 5. Given the strikingly different patterns of expression of CD38 and ART2, areas rich in B cells that express very high levels of CD38 but not ART2 (Fig. 2) can be predicted to be essentially ecto-NAD-free zones, because extracellular NAD will be rapidly degraded by CD38. In contrast, local levels of ecto-NAD may be sustained longer and at higher levels in areas rich in T cells, most of which express ART2 but little if any CD38 (Fig. 2).
Our results further illustrate that endogenous sources of ecto-NAD can affect T cell functions. Thus, a substantial fraction of freshly prepared T cells from CD38–/– but not from ART2–/– mice exposes PS on the cell surface (Fig. 8A) and lacks cell surface CD62L (B), whereas wild-type T cells show an intermediate phenotype. ART2-dependent PS exposure and shedding of CD62L both result from the activation of the P2X7 purinoceptor by ADP-ribosylation (7). C57BL/6 cells express a variant P2X7 receptor carrying the P451L mutation in the cytoplasmic domain, which strongly impairs P2X7-mediated signaling (17). Consistently, C57BL/6 T cells exhibit little if any spontaneous PS exposure or loss of CD62L (not shown). Considering that PS exposure and shedding of CD62L both occur within minutes after exposure of cells to NAD (7), it is possible that PS exposure and loss of CD62L by freshly prepared cells is induced by NAD released from cells lysed during cell preparation. Indeed, fresh preparations of lymph node cells consistently contain a small but distinct population of dead cells characterized by bright PI staining and small forward scatter, and these cells conceivably could have released their intracellular pool of NAD during cell preparation. Alternatively, T cells may have experienced NAD exposure in situ before sacrifice of the animal. In either case, the presence or absence of CD38 evidently profoundly affects the effective ecto-NAD concentration (Fig. 8). By analogy, NAD released from lysed cells during acute inflammation or tissue damage would be expected to exert strikingly different effects on T cells in vivo, depending on the presence or absence of CD38.
Only little is known about physiological and pathological release of NAD in vivo. Intracellular concentrations of NAD may reach millimolar levels, whereas steady-state serum levels of ecto-NAD are in the submicromolar range (23, 43). A substantial body of evidence indicates that nucleotides can be released from cells by nonlytic mechanisms, e.g., following mechanical shear forces or stimulation (23, 24, 27). Moreover, connexin 43 hemichannels may function as channels for the release of ATP and NAD (26). During infection, killed bacteria, yeast, and protozoa as well as lysed host cells represent additional potential sources of ecto-NAD. Of note, certain bacterial pathogens, e.g., Haemophilus influenzae, are known to lack endogenous NAD-synthesizing machinery and depend on ecto-NAD (44). Thus, relatively high levels of ecto-NAD can be predicted in the surroundings of lysed cells, especially in tissues lacking CD38 or expressing only low levels of CD38.
On the basis of our results, we speculate that elevated or sustained levels of ecto-NAD, as predicted to occur in CD38–/– mice under conditions of infection or tissue damage, lead to enhanced T cell death by triggering NAD-induced cell death via the ART2/P2X7 pathway and, subsequently, to an increased compensatory homeostatic proliferation of ART2-negative cells. Combined with a predisposing genetic background, enhanced homeostatic proliferation of T cells can precipitate autoimmune disease, as recently demonstrated in the case of the NOD mouse model for insulin-dependent diabetes mellitus (45). It should, therefore, be of great interest to determine whether CD38 deficiency affects T cell homeostasis in physiological and pathophysiological settings, and to determine whether the presence or absence of CD38 and/or ART2 affects the incidence or progression of autoimmune disease in NOD mice, which carry the wild-type P2X7 receptor (17).
Given the striking effect of CD38 on ART2-catalyzed ADP-ribosylation on T cells, it is not unlikely that CD38 also influences ADP-ribosylation by other members of the ART family. Cells in other tissues expressing high levels of CD38 can be expected to mediate locally low levels of ecto-NAD. CD38 is expressed in tissues, such as heart and reproductive organs, known to express other members of the ART family (5, 46, 47).
It has been proposed that nucleotides released from cells may function as signaling molecules (24). Our results support this notion and indicate that NAD itself may play a signaling role. On the basis of our findings, it is tempting to speculate that ART2 acts as a sensor of ecto-NAD levels, which translates the local concentration of ecto-NAD into corresponding levels of ADP-ribosylated cell surface proteins. The duration and intensity of exposure of cells to ecto-NAD in turn are determined by the local levels of CD38 on the cell surface or in the extracellular medium. In this scenario, the NAD-metabolizing ectoenzymes CD38 and ART2 together convey information about the presence of the signaling molecule ecto-NAD to lymphocytes and thereby may help to fine-tune immune responses.
|
Disclosures |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionDisclosuresReferences |
|---|
|
Acknowledgments |
|---|
|
Footnotes |
|---|
1 This work was supported by Deutsche Forschungsgemeinschaft Grants SFB 545/B9 and No310/6 (to F.K.-N. and F.H.), by stipends from the Werner Otto Foundation and the Boehringer Ingelheim Fonds (to C.K.), by a stipend from the Fondation pour la Recherche Medical (to S.A.), by National Institutes of Health Grant AI-057996 (to F.E.L.), and by National Institutes of Health Grants DK27722 and DK36175 (to E.H.L.). 
2 Address correspondence and reprint requests to Dr. Friedrich Koch-Nolte, Institute for Immunology, University Hospital, Martinistrasse 52, D-20246 Hamburg, Germany. E-mail address: nolte{at}uke.uni-hamburg.de
3 Abbreviations used in this paper: ART, ADP-ribosyltransferase; NADase, NAD-glycohydrolase; araF-NAD, nicotinamide 2'-deoxy-2'-fluoroarabinoside adenine dinucleotide; MFI, mean fluorescence intensity; PS, phosphatidylserine; PI, propidium iodide; etheno-NAD, nicotinamide 1,N6-ethenoadenine dinucleotide.
Received for publication November 24, 2004. Accepted for publication December 21, 2004.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionDisclosuresReferences |
|---|
-NAD. J. Biol. Chem. 267:9606.
-adrenoceptor stimulation in mouse aorta. J. Vet. Med. Sci. 65:1325.[Medline]
This article has been cited by other articles:
|
|
 |
|
  S. Hong, N. Schwarz, A. Brass, M. Seman, F. Haag, F. Koch-Nolte, W. P. Schilling, and G. R. Dubyak Differential Regulation of P2X7 Receptor Activation by Extracellular Nicotinamide Adenine Dinucleotide and Ecto-ADP-Ribosyltransferases in Murine Macrophages and T Cells J. Immunol., July 1, 2009; 183(1): 578 - 592. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Scheuplein, N. Schwarz, S. Adriouch, C. Krebs, P. Bannas, B. Rissiek, M. Seman, F. Haag, and F. Koch-Nolte NAD+ and ATP Released from Injured Cells Induce P2X7-Dependent Shedding of CD62L and Externalization of Phosphatidylserine by Murine T Cells J. Immunol., March 1, 2009; 182(5): 2898 - 2908. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Malavasi, S. Deaglio, A. Funaro, E. Ferrero, A. L. Horenstein, E. Ortolan, T. Vaisitti, and S. Aydin Evolution and Function of the ADP Ribosyl Cyclase/CD38 Gene Family in Physiology and Pathology Physiol Rev, July 1, 2008; 88(3): 841 - 886. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Mayo, J. Jacob-Hirsch, N. Amariglio, G. Rechavi, M.-J. Moutin, F. E. Lund, and R. Stein Dual Role of CD38 in Microglial Activation and Activation-Induced Cell Death J. Immunol., July 1, 2008; 181(1): 92 - 103. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Adriouch, P. Bannas, N. Schwarz, R. Fliegert, A. H. Guse, M. Seman, F. Haag, and F. Koch-Nolte ADP-ribosylation at R125 gates the P2X7 ion channel by presenting a covalent ligand to its nucleotide binding site FASEB J, March 1, 2008; 22(3): 861 - 869. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Hong, A. Brass, M. Seman, F. Haag, F. Koch-Nolte, and G. R. Dubyak Lipopolysaccharide, IFN-{gamma}, and IFN-beta Induce Expression of the Thiol-Sensitive ART2.1 Ecto-ADP-Ribosyltransferase in Murine Macrophages J. Immunol., November 1, 2007; 179(9): 6215 - 6227. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Koch-Nolte, J. Reyelt, B. Schossow, N. Schwarz, F. Scheuplein, S. Rothenburg, F. Haag, V. Alzogaray, A. Cauerhff, and F. A. Goldbaum Single domain antibodies from llama effectively and specifically block T cell ecto-ADP-ribosyltransferase ART2.2 in vivo FASEB J, November 1, 2007; 21(13): 3490 - 3498. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Adriouch, S. Hubert, S. Pechberty, F. Koch-Nolte, F. Haag, and M. Seman NAD+ Released during Inflammation Participates in T Cell Homeostasis by Inducing ART2-Mediated Death of Naive T Cells In Vivo J. Immunol., July 1, 2007; 179(1): 186 - 194. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. D. Liao and D. G. Puro NAD+-Induced Vasotoxicity in the Pericyte-Containing Microvasculature of the Rat Retina: Effect of Diabetes Invest. Ophthalmol. Vis. Sci., November 1, 2006; 47(11): 5032 - 5038. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Moreschi, S. Bruzzone, R. A. Nicholas, F. Fruscione, L. Sturla, F. Benvenuto, C. Usai, S. Meis, M. U. Kassack, E. Zocchi, et al. Extracellular NAD+ Is an Agonist of the Human P2Y11 Purinergic Receptor in Human Granulocytes J. Biol. Chem., October 20, 2006; 281(42): 31419 - 31429. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. O. Hassa, S. S. Haenni, M. Elser, and M. O. Hottiger Nuclear ADP-Ribosylation Reactions in Mammalian Cells: Where Are We Today and Where Are We Going? Microbiol. Mol. Biol. Rev., September 1, 2006; 70(3): 789 - 829. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-G. Chen, J. Chen, M. A. Osborne, H. D. Chapman, G. S. Besra, S. A. Porcelli, E. H. Leiter, S. B. Wilson, and D. V. Serreze CD38 Is Required for the Peripheral Survival of Immunotolerogenic CD4+ Invariant NK T Cells in Nonobese Diabetic Mice. J. Immunol., September 1, 2006; 177(5): 2939 - 2947. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Deaglio, T. Vaisitti, S. Aydin, E. Ferrero, and F. Malavasi In-tandem insight from basic science combined with clinical research: CD38 as both marker and key component of the pathogenetic network underlying chronic lymphocytic leukemia Blood, August 15, 2006; 108(4): 1135 - 1144. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Chen, Y.-G. Chen, P. C. Reifsnyder, W. H. Schott, C.-H. Lee, M. Osborne, F. Scheuplein, F. Haag, F. Koch-Nolte, D. V. Serreze, et al. Targeted Disruption of CD38 Accelerates Autoimmune Diabetes in NOD/Lt Mice by Enhancing Autoimmunity in an ADP-Ribosyltransferase 2-Dependent Fashion. J. Immunol., April 15, 2006; 176(8): 4590 - 4599. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kawamura, F. Aswad, M. Minagawa, S. Govindarajan, and G. Dennert P2X7 Receptors Regulate NKT Cells in Autoimmune Hepatitis J. Immunol., February 15, 2006; 176(4): 2152 - 2160. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Zolkiewska Ecto-ADP-ribose Transferases: Cell-Surface Response to Local Tissue Injury Physiology, December 1, 2005; 20(6): 374 - 381. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
) or with the supernatants of cells after a 20-min incubation with the indicated concentrations of etheno-NAD (
). The panel on the right shows a similar analysis for cells from CD38–/– mice. Results are representative of three independent experiments.
) mice were preincubated with the indicated concentrations of araF-NAD (0–2 µM) for 20 min before addition of 2 µM etheno-NAD and further incubation in the presence of araF-NAD and etheno-NAD for 20 min. Cells were washed and stained with 1G4Alexa488 and anti-B220PE before analysis by flow cytometry. Analysis of 1G4 staining was performed on cells gated for lack of B220 expression. B, Splenocytes obtained from C57BL/6 wild-type and CD38 knockout mice were preincubated without (
) for 15 min before addition of 2 µM etheno-NAD and further incubation for the indicated times. Cells were washed and stained with 1G4Alexa488 and anti-B220PE before analysis by flow cytometry. Analysis of 1G4 staining on gated cells (B220–) was performed as in A. Results are representative of three independent experiments.
